PTEN and breast cancer: In the tamoxifen plus everolimus (TAMRAD) and the BC Trials of Oral Everolimus-2 (BOLERO-2) studies, PTEN’s status fails to correlate with the response to everolimus treatment in BC patients (Treilleux et al., 2015).